71989-96-3

Basic information

• Product Name: 2,3,4-TRIMETHOXYBENZYL ALCOHOL
• Synonyms: (2,3,4-Trimethoxyphenyl)methanol;Benzenemethanol, 2,3,4-trimethoxy-;Benzyl alcohol, 2,3,4-trimethoxy-;2,3,4-TRIMETHOXYBENZYL ALCOHOL;RARECHEM AL BD 0024;2,3,4-Trimethoxybenzenemethanol;1-HydroxyMethyl-2,3,4-triMethoxybenzene;TriMetazidine EP IMpurity-D
• CAS NO: 71989-96-3
• Molecular Formula: C₁₀H₁₄O₄
• Molecular Weight: 198.22
• EINECS: 276-270-0
• Product Categories: Benzhydrols, Benzyl & Special Alcohols;Alcohols;C9 to C30;Oxygen Compounds;Aromatics;Impurities;Intermediates;Aromatics, Impurities, Intermediates
• Mol File: 71989-96-3.mol

Chemical Properties

• Boiling Point: 105 °C25 mm Hg(lit.)
• Flash Point: >230 °F
• Appearance: /
• Density: 1.151 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.000251mmHg at 25°C
• Refractive Index: n20/D 1.532(lit.)
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: Chloroform, Methanol
• PKA: 13.92±0.10(Predicted)
• CAS DataBase Reference: 2,3,4-TRIMETHOXYBENZYL ALCOHOL(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3,4-TRIMETHOXYBENZYL ALCOHOL(71989-96-3)
• EPA Substance Registry System: 2,3,4-TRIMETHOXYBENZYL ALCOHOL(71989-96-3)

Safety Data

• Safety Statements: 24/25
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 71989-96-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2,3,4-Trimethoxybenzyl alcohol is used as a synthetic intermediate for the introduction of a benzyl group onto the 2′-OH of purine ribonucleoside. This modification is crucial for the development of new pharmaceutical compounds with potential therapeutic applications.
Used in Drug Synthesis:
2,3,4-Trimethoxybenzyl alcohol is used as a key intermediate in the synthesis of various drugs, including the anti-anginal drug Trimetazidine (T795610). Its unique structure allows for the formation of specific chemical bonds and reactions that are essential for the creation of these medications.
Used in Quality Control and Impurity Testing:
As an impurity of Trimetazidine, 2,3,4-Trimethoxybenzyl alcohol is also used in the quality control and impurity testing of pharmaceutical products. Monitoring and controlling the presence of this compound in drug formulations ensures the safety, efficacy, and purity of the final product.

InChI:InChI=1/C10H14O4/c1-12-8-5-4-7(6-11)9(13-2)10(8)14-3/h4-5,11H,6H2,1-3H3

Upstream product

• 2103-57-3 2,3,4-trimethoxybenzaldehyde 
• 573-11-5 2,3,4-Trimethoxy-benzoic acid 

Downstream Products

• 1418220-39-9 2-((2,3,4-trimethoxybenzyl)thio)benzo[d]thiazole 
• 1370531-89-7 4-nitro-N-(2,3,4-trimethoxybenzyl)aniline 
• 80054-01-9 2,3,4-trimethoxybenzyl bromide 
• 1133-49-9 2,3,4-trimethoxybenzyl chloride 
• 409314-02-9 carbonic acid ethyl ester-(2,3,4-trimethoxy-benzyl ester) 
• 355396-89-3 N-(2,3,4-trimethoxybenzyl)aniline 
• 5011-34-7 1-(2,3,4-trimethoxybenzyl)piperazine 

Relevant articles and documents

Novel indole and triazole based hybrid molecules exhibit potent anti-adipogenic and antidyslipidemic activity by activating Wnt3a/β-catenin pathway

Obesity and dyslipidemia is the two facet of metabolic syndrome, which needs further attention. Recent studies indicate triazole and indole derivatives have remarkable anti-obesity/antidyslipidemic activity. To harness the above-mentioned potential, a series of novel triazole clubbed indole derivatives were prepared using click chemistry and evaluated for anti-adipogenic activity. Based on the structure-activity relationship, essential functional groups which potentiate anti-adipogenic activity were identified. The lead compound 13m exhibited potent anti-adipogenic activity compared to its parent compounds with the IC-50 value of 1.67 μM. Further evaluation of anti-adipogenic activity was conducted in different cell lines such as C3H10T1/2 and hMSC with positive result. The anti-adipogenic effect of compound 13m was most prominent in the early phase of adipogenesis, which is driven by the G1 to S phase cell cycle arrest during mitotic clonal expansion. The mechanistic study suggests that compound 13m exhibit anti-adipogenic property by activating Wnt3a/β-catenin pathway, a known suppressor of key adipogenic genes PPARγ and C/EBPα. It is noteworthy that the compound 13m also reduced serum triglyceride, LDL and total cholesterol in Syrian Golden hamster model of dyslipidemia. The anti-adipogenic activity of compound 13m can also be correlated with decreased expression of PPARγ and increased expression of β-catenin in epididymal white adipose tissue (eWAT) in vivo. The compound 13m also increased the expression of genes involved in reverse cholesterol transport (RCT) such as PPARα and LXR1α indicating another mechanism by which compound 13m ameliorates dyslipidemia in Syrian Golden hamster model. Overall this study provides a unique perspective into the anti-adipogenic/antidyslipidemic property of triazole and indole hybrids molecules with further scope to increase the anti-adipogenic potency for therapeutic intervention of obesity and metabolic syndrome.

TUBULIN BINDING AGENTS

The invention provides combretastatin A-4 like compounds that are modified to have enhanced tubulin binding activity and in some embodiments the ability to promote accumulation in the vasculature undergoing angiogenesis (homing activity). The compounds are based on the combretastatin A-4 skeletal structure having a tubulin-binding pharmacophore comprising two fused rings (A and B rings) in which the B ring is substituted with (a) an aromatic ring structure (C ring) and (b) a second substituent/functional group that comes off the B ring. The aromatic ring structure is typically a six membered ring phenolic or aniline structure, or may also be a fused ring structure such as a substituted or unsubstituted naphthalene. The second substituent on the B ring may for example be a substituent which has been found to provide enhanced tubulin binding activity (for example a carbonyl group), or may be a substituent that facilitates functionalisation of the B ring (for example an hydroxyl or amine group), or it may be a binding agent for a target that is preferentially expressed on vasculature undergoing angiogenesis, and not expressed on quiescent vasculature.

Zinc phthalocyanine with PEG-400 as a recyclable catalytic system for selective reduction of aromatic nitro compounds

Zinc phthalocyanine with PEG-400 was established as a catalytic system for chemo and regioselective reduction of aromatic nitro compounds to corresponding amines. A large range of reducible functional groups such as acid, amide, ester, halogen, lactone, nitrile, N-benzyl, O-benzyl, hydroxy and heterocycles were well tolerated. Direct synthesis of benzotriazole from O-dinitrobenzene was achieved for the first time. The present catalytic system was successfully employed for the reduction of carbonyl and ester compounds to corresponding alcohols and reductive amination of benzaldehydes with primary amines to form corresponding secondary amines. Remarkable advantages of the present catalytic method include low loading of metal, avoidance of toxic ligands and high isolated yields. The catalyst was recyclable up to four times without any loss of selectivity and activity.

Synthesis and in vitro antibacterial activity of gemifloxacin derivatives containing a substituted benzyloxime moiety

A series of novel gemifloxacin (GMFX) derivatives containing a substituted benzyloxime moiety with remarkable improvement in lipophilicity were synthesized. The target compounds evaluated for their in vitro antibacterial activity against representative strains. Our results reveal that most of the target compounds have considerable potency against all of the tested Gram-positive strains including MRSA and MRSE (MIC: 90: 1 μg/mL) is 8-fold more active than GMFX, and 2-fold more active than GMFX and moxifloxacin against MRSE clinical isolates (MIC90: 4 μg/mL). Crown Copyright

Anellated dihydropyridines and the use thereof for the production of pharmaceutical preparation

Compound of general formula I STR1 wherein A is a benzo or thieno group; R1 is (C4-6)cycloalkyl, (C4-6)cycloalkyl-(C1-5)alkyl or STR2 R2, m, R3, R4, R and u are defined as in the specification, and pharmaceutical preparations containing this compound and the new pharmaceutical uses thereof.

Cobalt(II) chloride hexahydrate-zinc-dimethylformamide-water: An efficient system for reduction of aldehydes to alcohols

The system cobalt(II) chloride hexahydrate-zinc-dimethylformamide-water converts aldehydes to the corresponding alcohols at room temperature in excellent yields.

An efficient reduction system - NiCl2·6H2O-Zn/DMF-H2O for conversion of aldehydes to alcohols

Aldehydes were efficiently converted to the corresponding alcohols at room temperature, with NiCl2·6H2O-Zn/DMF-H2O system.

Ruthenium catalyst for biarylic coupling; new steganolides

A method for forming bridged biaryl compounds via the intramolecular oxidative biarylic coupling of precursor compounds containing two aromatic rings linked via a hydrocarbon chain is disclosed along with the ruthenium catalyst for its implementation and new compounds resulting therefrom. The biarylic coupling method is characterized in that the biarylic precursors are cyclized in the presence of the catalyst tetrakis(trifluoroacetate) of ruthenium (IV).

ISOLEMENT, ETUDE STEREOCHIMIQUE ET SYNTHESE BIOMIMETIQUE DU STEGANOLIDE A, NOUVEAU LIGNANE BISBENZOCYCLOOCTADIENOLACTONIQUE DE STEGANOTAENIA ARALIACEA

Isolation of steganolide A from Steganotaenia araliacea (Apiaceae) - a new original bisbenzocyclooctadiene lignan lactone bearing an "iso" = M-6R biaryl junction (P,M, = Plus, Minus in terms of helicity nomenclature applied to axial chirality) - and short biomimetic total synthesis using intramolecular nonphenolic oxydative biaryl coupling as a key reaction were performed.